176 related articles for article (PubMed ID: 37182989)
21. Stereotactic ablative radiotherapy and systemic treatments for extracerebral oligometastases, oligorecurrence, oligopersistence and oligoprogression from lung cancer.
Kissel M; Martel-Lafay I; Lequesne J; Faivre JC; Le Péchoux C; Stefan D; Barraux V; Loiseau C; Grellard JM; Danhier S; Lerouge D; Chouaid C; Gervais R; Thariat J
BMC Cancer; 2019 Dec; 19(1):1237. PubMed ID: 31856742
[TBL] [Abstract][Full Text] [Related]
22. [Stereotaxic ablative radiotherapy in stage 1 non-small-cell lung cancer: Results of the phase 3 randomized trial "CHISEL"].
Gerard M; Lerouge D; Le Guevelou J; Thariat J
Bull Cancer; 2020 Feb; 107(2):145-147. PubMed ID: 32035650
[No Abstract] [Full Text] [Related]
23. To SABR or not to SABR? Indications and contraindications for stereotactic ablative radiotherapy in the treatment of early-stage, oligometastatic, or oligoprogressive non-small cell lung cancer.
Shultz DB; Diehn M; Loo BW
Semin Radiat Oncol; 2015 Apr; 25(2):78-86. PubMed ID: 25771411
[TBL] [Abstract][Full Text] [Related]
24. Oligoprogression in non-small cell lung cancer: a narrative review.
Nguyen KT; Sakthivel G; Milano MT; Qiu H; Singh DP
J Thorac Dis; 2022 Dec; 14(12):4998-5011. PubMed ID: 36647502
[TBL] [Abstract][Full Text] [Related]
25. Ultra-central Thoracic Re-irradiation Using 10-fraction Stereotactic Body Radiotherapy for Recurrent Non-small-cell Lung Cancer Tumors: Preliminary Toxicity and Efficacy Outcomes.
Sood S; Ganju R; Shen X; Napel MT; Wang F
Clin Lung Cancer; 2021 May; 22(3):e301-e312. PubMed ID: 33132058
[TBL] [Abstract][Full Text] [Related]
26. American Radium Society Appropriate Use Criteria for Radiation Therapy in Oligometastatic or Oligoprogressive Non-Small Cell Lung Cancer.
Amini A; Verma V; Simone CB; Chetty IJ; Chun SG; Donington J; Edelman MJ; Higgins KA; Kestin LL; Movsas B; Rodrigues GB; Rosenzweig KE; Rybkin II; Slotman BJ; Wolf A; Chang JY
Int J Radiat Oncol Biol Phys; 2022 Feb; 112(2):361-375. PubMed ID: 34571054
[TBL] [Abstract][Full Text] [Related]
27. Stereotactic radiotherapy in oligometastatic cancer.
Kennedy TAC; Corkum MT; Louie AV
Chin Clin Oncol; 2017 Sep; 6(Suppl 2):S16. PubMed ID: 28917254
[TBL] [Abstract][Full Text] [Related]
28. Stereotactic Ablative Radiotherapy Using CyberKnife for Stage I Non-small-cell Lung Cancer: A Retrospective Analysis.
Hayashi K; Suzuki O; Shiomi H; Nakai M; Fujiwara K; Nakanishi E; Tatekawa S; Hirata T; Tamari K; Hirata H; Funaki S; Seo Y; Takeda Y; Isohashi F; Shintani Y; Ogawa K
Anticancer Res; 2022 Jan; 42(1):321-327. PubMed ID: 34969740
[TBL] [Abstract][Full Text] [Related]
29. Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial.
Iyengar P; Wardak Z; Gerber DE; Tumati V; Ahn C; Hughes RS; Dowell JE; Cheedella N; Nedzi L; Westover KD; Pulipparacharuvil S; Choy H; Timmerman RD
JAMA Oncol; 2018 Jan; 4(1):e173501. PubMed ID: 28973074
[TBL] [Abstract][Full Text] [Related]
30. Correlation of biologically effective dose and the tumor control in Stage I (<5 cm) non-small cell lung cancer with stereotactic ablative radiotherapy: a single institutional cohort study.
Jeon W; Ahn SJ; Kim YC; Oh IJ; Park CK; Jeong JU; Yoon MS; Song JY; Nam TK; Chung WK
Jpn J Clin Oncol; 2018 Feb; 48(2):144-152. PubMed ID: 29194510
[TBL] [Abstract][Full Text] [Related]
31. Integration of Stereotactic Body Radiation Therapy With Tyrosine Kinase Inhibitors in Stage IV Oncogene-Driven Lung Cancer.
Campo M; Al-Halabi H; Khandekar M; Shaw AT; Sequist LV; Willers H
Oncologist; 2016 Aug; 21(8):964-73. PubMed ID: 27354669
[TBL] [Abstract][Full Text] [Related]
32. Clinical outcomes of stereotactic ablative radiotherapy in patients with pulmonary metastasis.
Jang BS; Kim HJ; Kim BH; Kim DW; Kim YT; Kim YW; Jang MJ; Wu HG
Jpn J Clin Oncol; 2017 Jan; 47(1):61-66. PubMed ID: 28122893
[TBL] [Abstract][Full Text] [Related]
33. Stereotactic ablative radiotherapy for early stage non-small cell lung cancer: A critical literature review of predictive factors of relapse.
Loganadane G; Martinetti F; Mercier O; Krhili S; Riet FG; Mbagui R; To H; Le Péchoux C; Levy A
Cancer Treat Rev; 2016 Nov; 50():240-246. PubMed ID: 27768919
[TBL] [Abstract][Full Text] [Related]
34. Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial.
Ball D; Mai GT; Vinod S; Babington S; Ruben J; Kron T; Chesson B; Herschtal A; Vanevski M; Rezo A; Elder C; Skala M; Wirth A; Wheeler G; Lim A; Shaw M; Schofield P; Irving L; Solomon B;
Lancet Oncol; 2019 Apr; 20(4):494-503. PubMed ID: 30770291
[TBL] [Abstract][Full Text] [Related]
35. Metastasis-directed Therapy Prolongs Efficacy of Systemic Therapy and Improves Clinical Outcomes in Oligoprogressive Castration-resistant Prostate Cancer.
Deek MP; Taparra K; Phillips R; Velho PI; Gao RW; Deville C; Song DY; Greco S; Carducci M; Eisenberger M; DeWeese TL; Denmeade S; Pienta K; Paller CJ; Antonarakis ES; Olivier KR; Park SS; Tran PT; Stish BJ
Eur Urol Oncol; 2021 Jun; 4(3):447-455. PubMed ID: 32536574
[TBL] [Abstract][Full Text] [Related]
36. Stereotactic Body Radiotherapy and Ablative Therapies for Lung Cancer.
Abbas G; Danish A; Krasna MJ
Surg Oncol Clin N Am; 2016 Jul; 25(3):553-66. PubMed ID: 27261915
[TBL] [Abstract][Full Text] [Related]
37. Study protocol for the SARON trial: a multicentre, randomised controlled phase III trial comparing the addition of stereotactic ablative radiotherapy and radical radiotherapy with standard chemotherapy alone for oligometastatic non-small cell lung cancer.
Conibear J; Chia B; Ngai Y; Bates AT; Counsell N; Patel R; Eaton D; Faivre-Finn C; Fenwick J; Forster M; Hanna GG; Harden S; Mayles P; Moinuddin S; Landau D
BMJ Open; 2018 Apr; 8(4):e020690. PubMed ID: 29666135
[TBL] [Abstract][Full Text] [Related]
38. Toxicity and Efficacy of Stereotactic Ablative Body Radiotherapy for Moderately Central Non-small Cell Lung Cancers Using 50 Gy in Five Fractions.
Rulach R; McLoone P; Lumsden G; McKay S; MacLaren V; Macphee J; Moore K; Omand M; Sproule M; Currie S; Aitken A; Ferguson R; Valentine R; Houston P; Harrow S; Hicks J
Clin Oncol (R Coll Radiol); 2020 Apr; 32(4):250-258. PubMed ID: 31607611
[TBL] [Abstract][Full Text] [Related]
39. Stereotactic Ablative Radiation Therapy for Large (≥5 cm) Non-small Cell Lung Carcinoma.
McDermott RL; Mihai A; Dunne M; Keys M; O'Sullivan S; Thirion P; ElBeltagi N; Armstrong JG
Clin Oncol (R Coll Radiol); 2021 May; 33(5):292-299. PubMed ID: 33309479
[TBL] [Abstract][Full Text] [Related]
40. Accelerated Hypofractionated Radiotherapy Versus Stereotactic Body Radiotherapy for the Treatment of Stage I Nonsmall Cell Lung Cancer-A Single Institution Experience With Long-Term Follow-Up.
Karasawa K; Hayakawa S; Machitori Y; Shibata Y; Ogawa H; Ito K; Shimizuguchi T; Kawamoto T; Nihei K
Technol Cancer Res Treat; 2018 Jan; 17():1533033818806318. PubMed ID: 30317929
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]